Biogen (BIIB)
(Delayed Data from NSDQ)
$204.76 USD
-0.06 (-0.03%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $204.61 -0.15 (-0.07%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$204.76 USD
-0.06 (-0.03%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $204.61 -0.15 (-0.07%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
Zacks News
Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Biogen Inc. (BIIB) closed at $206.94, marking a -0.02% move from the previous day.
Biotech Stock Roundup: GILD's COVID-19 Drug Update, AXSM Down on Regulatory News
by Zacks Equity Research
Regulatory and pipeline updates from Gilead (GILD) and Axsome (AXSM) are a few key highlights from the biotech sector during the past week.
Incyte (INCY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Incyte's (INCY) top line is likely to have been driven in the first quarter by the sales of its lead drug, Jakafi.
Will Biogen (BIIB) Succeed in Beating Q1 Earnings Estimates?
by Zacks Equity Research
Biogen's (BIIB) multiple sclerosis revenues have been declining since the past few quarters. It is unlikely that MS sales have improved in the first quarter.
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Eli Lilly (LLY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) first-quarter sales.
Biogen Inc. (BIIB) Stock Moves -0.92%: What You Should Know
by Zacks Equity Research
In the latest trading session, Biogen Inc. (BIIB) closed at $218.40, marking a -0.92% move from the previous day.
Prothena (PRTA) Stock Gains 51% in a Year: What Lies Ahead?
by Zacks Equity Research
Prothena (PRTA) has had a phenomenal run in the past year, primarily due to its promising pipeline for AD.
Why Biogen Inc. (BIIB) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Biogen Inc. (BIIB) Stock Moves -0.67%: What You Should Know
by Zacks Equity Research
In the latest trading session, Biogen Inc. (BIIB) closed at $212.55, marking a -0.67% move from the previous day.
INmune (INMB) Begins Dosing in Mid-Stage Study With AD Candidate
by Zacks Equity Research
INmune (INMB) doses the first patient in a phase II study with its investigational TNF inhibitor to treat Alzheimer's disease. Stock rises more than 12% post this announcement.
Biogen Inc. (BIIB) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Biogen Inc. (BIIB) closed at $214.75, marking a +1.47% move from the previous day.
Biogen (BIIB) Down as Medicare Limits Coverage for Aduhelm
by Zacks Equity Research
Biogen (BIIB) stock declines after Medicare limits coverage for FDA-approved Alzheimer's drugs like Aduhelm only for patients enrolled in CMS-approved studies.
Biogen Inc. (BIIB) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Biogen Inc. (BIIB) closed the most recent trading day at $211.64, moving +0.47% from the previous trading session.
Advanced Micro Devices and Biogen have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Advanced Micro Devices and Biogen are part of Zacks Bull and Bear of the Day article.
Bear of the Day: Biogen (BIIB)
by Kevin Cook
Generic sales hit MS franchise and Alzheimer's treatment is slow starter: EPS forecasts down 20%
Biogen (BIIB) Plans to Start Aduhelm Confirmatory Study in May
by Zacks Equity Research
Biogen (BIIB) expects to start the phase IV post-marketing confirmatory study of Aduhelm for Alzheimer's disease in May 2022. The estimated completion period of the study is four years.
Phreesia (PHR) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Phreesia (PHR) delivered earnings and revenue surprises of 14.29% and 3.93%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: AXSM to Acquire JAZZ's Drug, IGMS Up on SNY Deal & More
by Zacks Equity Research
Acquisition and collaboration news from Axsome (AXSM) and IGM Biosciences, Inc. (IGMS), respectively, are a few key highlights from the biotech sector during the past week.
Biogen (BIIB), Ionis to End Early-Stage ALS Candidate Development
by Zacks Equity Research
Biogen (BIIB) & partner Ionis (IONS) to terminate the development of their antisense ALS candidate, as the drug failed to show any clinical benefit in an early-stage study for C9orf72-associated ALS.
Prothena (PRTA) IND Application Gets FDA Clearance for AD
by Zacks Equity Research
Prothena (PRTA) application for evaluating PRX012 for the treatment of Alzheimer's disease (AD) gets FDA clearance.
Biogen Inc. (BIIB) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Biogen Inc. (BIIB) closed at $211.68, marking a +0.34% move from the previous day.
Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Biogen Inc. (BIIB) closed at $206.81, marking a -0.84% move from the previous day.
Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Biogen Inc. (BIIB) closed at $193.77 in the latest trading session, marking a -1.97% move from the prior day.
Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Biogen Inc. (BIIB) closed at $198.64, marking a -1.79% move from the previous day.